MedPath

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Completed
Conditions
Multiple Myeloma
Interventions
Drug: Standard of care
Registration Number
NCT06592222
Lead Sponsor
Pfizer
Brief Summary

This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, the investigators will use data from the phase 2 clinical trial (MagnetisMM-3). The investigators will also use data from a real-world data source, representing the SOC in clinical practice. This study does not seek any participants for enrollment. The investigators will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help the investigators to know how well elranatamab can be used for RRMM treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4
Inclusion Criteria
  • Aged 18 years and older at index date
  • Diagnosis of MM
  • Measurable disease according to IMWG criteria
  • ECOG performance status ≤2
  • Refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 treatment (ie, triple-class refractory [TCR])
  • At least 1 treatment following their TCR eligibility
Exclusion Criteria
  • Acute plasma cell leukemia
  • Amyloidosis
  • Smoldering MM
  • Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)
  • Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ
  • Administration with an investigational drug within 30 days prior to index

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ElranatamabElranatamabPatients treated with elranatamab from the MagnetisMM-3 trial
Standard of careStandard of carePatients treated with standard-of-care therapies from real-world data sources
Primary Outcome Measures
NameTimeMethod
Progression-free survivalFrom the index therapy start until progression or death due to any cause, whichever occurs first, assessed up to 6 years
Secondary Outcome Measures
NameTimeMethod
Overall surivalFrom the index therapy start until death due to any cause assessed up to 6 years
Duration of responseFrom the first documentation of objective response until progression or death due to any cause, whichever occurs first, assessed up to 6 years

Trial Locations

Locations (1)

Pfizer

🇺🇸

New York, New York, United States

Pfizer
🇺🇸New York, New York, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.